Weed (BUDZ) Net Income towards Common Stockholders (2010 - 2026)
Weed (BUDZ) posted quarterly Net Income towards Common Stockholders of -$175256.0 for Q1 2026, up 60.21% year-over-year from -$109391.3 in Q1 2025, and up 91.74% quarter-over-quarter from -$2.1 million in Q4 2025.
Weed (BUDZ) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Weed's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$175256.0 for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 60.21% year-over-year to -$175256.0; the TTM figure through Mar 2026 stood at -$2.5 million (down 217.63% YoY), while the FY2025 annual figure was -$2.7 million, down 437.35% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$175256.0, up from -$2.1 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $734248.0 in Q3 2023, with the low at -$4.0 million in Q2 2023.
- The 5-year median for Net Income towards Common Stockholders is -$192312.0 (2022), against an average of -$989428.2.
- The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders plunged 1543.81% in 2022, then soared 124.53% in 2023.
- Weed's Net Income towards Common Stockholders stood at -$192312.0 in 2022, then tumbled by 105.07% to -$394368.0 in 2023, then surged by 66.22% to -$133224.0 in 2024, then tumbled by 1493.05% to -$2.1 million in 2025, then jumped by 91.74% to -$175256.0 in 2026.
- Business Quant data shows BUDZ's Net Income towards Common Stockholders at -$175256.0 in Q1 2026, -$2.1 million in Q4 2025, and -$73946.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Weed | 2.88 Mn | 2.88 Mn | - | -104,132.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,256.00 |
| Dec 31, 2025 | -2.12 Mn |
| Sep 30, 2025 | -73,946.00 |
| Jun 30, 2025 | -107,616.00 |
| Mar 31, 2025 | -440,455.00 |
| Dec 31, 2024 | -133,224.00 |
| Sep 30, 2024 | -95,887.00 |
| Jun 30, 2024 | -110,953.00 |
| Mar 31, 2024 | -170,652.00 |
| Dec 31, 2023 | -394,368.00 |
| Sep 30, 2023 | 734,248.00 |
| Jun 30, 2023 | -3.99 Mn |
| Mar 31, 2023 | -197,014.00 |
| Dec 31, 2022 | -192,312.00 |
| Sep 30, 2022 | -2.99 Mn |
| Jun 30, 2022 | -3.08 Mn |
| Mar 31, 2022 | -3.28 Mn |
| Dec 31, 2021 | -467,504.00 |
| Sep 30, 2021 | -182,101.00 |
| Jun 30, 2021 | -1.22 Mn |